A novel complement therapeutic CTx001 offers a novel approach to treating geographic atrophy. Complement Therapeutics (CTx) is a Germany-based preclinical stage biotechnology company focusing on the R ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven diseases. The partnership will leverage ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...

- Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) ...

Round led by Gimv, a Belgian based private equity and venture capital firm Round comes just 1 year after raising €5 million seed funding in February 2022 Company aims to transform the treatment of ...

“Our CAN106 program for complement-mediated diseases is gaining momentum this year with the first public presentation of the Phase 1 clinical trial results at two major scientific conferences and the ...

A preclinical biotechnology company, spun out of The University of Manchester, has announced the completion of a €72 million finance deal to develop the treatment of a leading cause of blindness. The ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...